Zacks Investment Research on MSN
IRWD rises 307% in 6 months: Is this an indication to buy the stock?
Shares of Ironwood Pharmaceuticals IRWD have risen sharply over the past six months, primarily driven by the improving demand for its sole marketed product, Linzess (linaclotide) and the company’s ...
Zacks Investment Research on MSN
Does Ironwood's bullish 2026 view signal greater Linzess adoption?
Ironwood Pharmaceuticals IRWD has been witnessing improved demand for its sole marketed product, Linzess (linaclotide), in ...
– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% ...
Many Medicare Part D plans cover Linzess, but out-of-pocket costs can vary because private insurance companies manage these plans. Linzess is an expensive medication with no generic alternatives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results